Biomedical Engineering Reference
In-Depth Information
35. Jamroziak K, Balcerczak E, Cebula B, Kowalczyk M, Panczyk M, Janus A, Smolewski
P, Mirowski M, Robak T. 2005. Multi-drug transporter MDR1 gene polymorphism and
prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep 57: 882-888.
36. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. 2003.
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemother-
apy in locally advanced breast cancer. Int J Oncol 22: 1117-1121.
37. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. 2006. mdr-1 single-
nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response
to paclitaxel chemotherapy. Clin Cancer Res 12: 854-859.
38. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H. 2002. Role of
human MDR1 gene polymorphisms in bioavailability: interaction of digoxin, a substrate
of P-glycoprotein. Clin Pharmacol Ther 72: 209-219.
39. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding
cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
40. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance
in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and
vinblastin by verapamil. Cancer Res 41: 1967-1972.
41. Sikic BI. 1997. Pharmacological approaches to reversing multidrug resistance. Semin
Hematol 34: 40-47.
42. Sikic BI. 1999. New approaches in cancer treatment. Ann Oncol 10: 149-153.
43. De Bruin M, Miyake K, Litman T, Robey R, Bates SE. 1999. Reversal of resistance by
GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:
117-126.
44. Pauli-Magnus C, Rekersbrink S, Kloz U, Gromm MF. 2001. Interaction of omeprazole,
lansoprazole and pantoprazole with P-glycoprotein. Arch Pharmacol 364: 551-557.
45. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel
AH, van Tellingen O, Borst P, Schellens JHM. 2004. Mechanism of the pharmacoki-
netic interaction between methotrexate and benzimidazoles: potential role for breast
cancer resistance protein in clinical drug-drug interactions. Cancer Res 16: 5804-
58011.
46. Reid T, Yuen A, Catolico M, Carlson RW. 1993. Impact of omeprazole on the plasma
clearance of methotrexate. Cancer Chemother Pharmacol 33: 82-84.
47. Mannesse CK, Derkx FH, de Ridder MA, Man in't veld AJ, van der Cammen TJ. 2000.
Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing
29: 35-39.
48. Troger U, Stotzel B, Martens-Lobenhoffe J, Gollnick H, Meijer FP. 2002. Drug Points: Se-
vere myalgia from an interaction between treatments with pantoprazole and methotrexate.
Br Med J 22: 1497.
49. De Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. 2003. Drug
interactions between antiretroviral drugs and comedication. Clin Pharmacokinet 42: 223-
282.
50. DuBuske LM. 2005. The role of P-glycoprotein and organic anion-transporting polypep-
tides in drug interactions. Drug Saf 28: 789-801.
51. Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. 2004. P-Glycoprotein
in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents
Chemother 48: 1073-1081.
Search WWH ::
Custom Search